Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (82)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Peters, J. M.
Right arrow Articles by Gonzalez, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Peters, J. M.
Right arrow Articles by Gonzalez, F. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 1989-1994, Copyright © 1998 by Oxford University Press

ARTICLES

Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver

JM Peters, T Aoyama, RC Cattley, U Nobumitsu, T Hashimoto and FJ Gonzalez
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. jpeters@helix.nih.gov

The mechanisms underlying peroxisome proliferator-induced hepatocarcinogenesis are unclear but are mediated by the peroxisome proliferator-activated receptor alpha (PPARalpha). To determine the role of PPARalpha in the mechanisms of hepatocarcinogenesis, the effect of Wy-14,643 on expression patterns of acyl CoA oxidase (ACO) and proteins involved in cell proliferation in the PPARalpha-null mouse were evaluated. ACO, CDK-1, CDK-2, CDK-4, PCNA and c-myc proteins were significantly increased in wild-type mice fed Wy-14,643 for 5 weeks or 11 months, as compared with controls. This effect was not observed in Wy-14,643-treated PPARalpha-null mice. Expression patterns of cyclin B1, cyclin D, cyclin E and p53 were not different in any of the groups. mRNAs encoding CDK-1, CDK-4, cyclin D1 and c-myc were also increased in wild-type mice fed Wy-14,643 but not in PPARalpha-null mice. These results indicate that the increase in CDK-1, CDK-4 and c-myc may be caused by an increase in transcription that is mediated directly or indirectly by PPARalpha. Thus PPARalpha-dependent alterations in cell cycle regulatory proteins induced by peroxisome proliferators are likely to contribute to the hepatocarcinogenicity of peroxisome proliferators.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
K. Kono, Y. Kamijo, K. Hora, K. Takahashi, M. Higuchi, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, and T. Aoyama
PPAR{alpha} attenuates the proinflammatory response in activated mesangial cells
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F328 - F336.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. B. Rosen, J. S. Lee, H. Ren, B. Vallanat, J. Liu, M. P. Waalkes, B. D. Abbott, C. Lau, and J. C. Corton
Toxicogenomic Dissection of the Perfluorooctanoic Acid Transcript Profile in Mouse Liver: Evidence for the Involvement of Nuclear Receptors PPAR{alpha} and CAR
Toxicol. Sci., May 1, 2008; 103(1): 46 - 56.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Kamijo, K. Hora, K. Kono, K. Takahashi, M. Higuchi, T. Ehara, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, and T. Aoyama
PPAR{alpha} Protects Proximal Tubular Cells from Acute Fatty Acid Toxicity
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3089 - 3100.
[Full Text] [PDF]

Home page
 Toxicol SciHome page
C. G. Woods, A. M. Burns, B. U. Bradford, P. K. Ross, O. Kosyk, J. A. Swenberg, M. L. Cunningham, and I. Rusyn
WY-14,643 Induced Cell Proliferation and Oxidative Stress in Mouse Liver are Independent of NADPH Oxidase
Toxicol. Sci., August 1, 2007; 98(2): 366 - 374.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn
Genomic Profiling in Nuclear Receptor-Mediated Toxicity
Toxicol Pathol, June 1, 2007; 35(4): 474 - 494.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Q. Yang, S. Ito, and F. J. Gonzalez
Hepatocyte-restricted constitutive activation of PPAR{alpha} induces hepatoproliferation but not hepatocarcinogenesis
Carcinogenesis, June 1, 2007; 28(6): 1171 - 1177.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Kamijo, K. Hora, T. Nakajima, K. Kono, K. Takahashi, Y. Ito, M. Higuchi, K. Kiyosawa, H. Shigematsu, F. J. Gonzalez, et al.
Peroxisome Proliferator-Activated Receptor {alpha} Protects against Glomerulonephritis Induced by Long-Term Exposure to the Plasticizer Di-(2-Ethylhexyl)Phthalate
J. Am. Soc. Nephrol., January 1, 2007; 18(1): 176 - 188.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Yang, R. Kurotani, A. Yamada, S. Kimura, and F. J. Gonzalez
Peroxisome Proliferator-Activated Receptor {alpha} Activation during Pregnancy Severely Impairs Mammary Lobuloalveolar Development in Mice
Endocrinology, October 1, 2006; 147(10): 4772 - 4780.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K. Morimura, C. Cheung, J. M. Ward, J. K. Reddy, and F. J. Gonzalez
Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor {alpha} to Wy-14,643-induced liver tumorigenesis
Carcinogenesis, May 1, 2006; 27(5): 1074 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. A. Peraza, A. D. Burdick, H. E. Marin, F. J. Gonzalez, and J. M. Peters
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Toxicol. Sci., April 1, 2006; 90(2): 269 - 295.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
N. Ouyang, J. L. Williams, and B. Rigas
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR){delta} expression in APCmin/+ mice proportionally to their tumor inhibitory effect: Implications for the role of PPAR{delta} in carcinogenesis
Carcinogenesis, February 1, 2006; 27(2): 232 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. P. Gray, J. W. Davis II, L. Gopinathan, T. L. Leas, C. A. Nugent, and J. P. Vanden Heuvel
The Ribosomal Protein rpL11 Associates with and Inhibits the Transcriptional Activity of Peroxisome Proliferator-Activated Receptor-{alpha}
Toxicol. Sci., February 1, 2006; 89(2): 535 - 546.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
N. F. Cariello, E. H. Romach, H. M. Colton, H. Ni, L. Yoon, J. G. Falls, W. Casey, D. Creech, S. P. Anderson, G. R. Benavides, et al.
Gene Expression Profiling of the PPAR-alpha Agonist Ciprofibrate in the Cynomolgus Monkey Liver
Toxicol. Sci., November 1, 2005; 88(1): 250 - 264.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Hays, I. Rusyn, A. M. Burns, M. J. Kennett, J. M. Ward, F. J. Gonzalez, and J. M. Peters
Role of peroxisome proliferator-activated receptor-{alpha} (PPAR{alpha}) in bezafibrate-induced hepatocarcinogenesis and cholestasis
Carcinogenesis, January 1, 2005; 26(1): 219 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cheung, T. E. Akiyama, J. M. Ward, C. J. Nicol, L. Feigenbaum, C. Vinson, and F. J. Gonzalez
Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor {alpha}
Cancer Res., June 1, 2004; 64(11): 3849 - 3854.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
F. Yadetie, A. Laegreid, I. Bakke, W. Kusnierczyk, J. Komorowski, H. L. Waldum, and A. K. Sandvik
Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-{alpha} agonist ciprofibrate
Physiol Genomics, September 29, 2003; 15(1): 9 - 19.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. S. Tien, J. P. Gray, J. M. Peters, and J. P. Vanden Heuvel
Comprehensive Gene Expression Analysis of Peroxisome Proliferator-treated Immortalized Hepatocytes: Identification of Peroxisome Proliferator-activated Receptor {alpha}-dependent Growth Regulatory Genes
Cancer Res., September 15, 2003; 63(18): 5767 - 5780.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. L. O'Brien, M. L. Cunningham, B. T. Spear, and H. P. Glauert
Peroxisome Proliferators Do Not Activate the Transcription Factors AP-1, Early Growth Response-1, or Heat Shock Factors 1 and 2 in Rats or Hamsters
Toxicol. Sci., September 1, 2002; 69(1): 139 - 148.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. P. Anderson, C. S. Dunn, R. C. Cattley, and J.C. Corton
Hepatocellular proliferation in response to a peroxisome proliferator does not require TNF{alpha} signaling
Carcinogenesis, November 1, 2001; 22(11): 1843 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
T. E. Akiyama, C. J. Nicol, C. Fievet, B. Staels, J. M. Ward, J. Auwerx, S. S. T. Lee, F. J. Gonzalez, and J. M. Peters
Peroxisome Proliferator-activated Receptor-alpha Regulates Lipid Homeostasis, but Is Not Associated with Obesity. STUDIES WITH CONGENIC MOUSE LINES
J. Biol. Chem., October 12, 2001; 276(42): 39088 - 39093.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Kiss, R. Ortiz-Aguayo, R. Sharp, G. Merlino, S. S. Thorgeirsson, F. J. Gonzalez, and J. M. Peters
Evidence that reduction of hepatocyte growth factor (HGF) is not required for peroxisome proliferator-induced hepatocyte proliferation
Carcinogenesis, June 1, 2001; 22(6): 975 - 979.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
J. M. Peters, S. S. T. Lee, W. Li, J. M. Ward, O. Gavrilova, C. Everett, M. L. Reitman, L. D. Hudson, and F. J. Gonzalez
Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor beta (delta )
Mol. Cell. Biol., July 15, 2000; 20(14): 5119 - 5128.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
J. M. Peters, I. Rusyn, M. L. Rose, F. J. Gonzalez, and R. G. Thurman
Peroxisome proliferator-activated receptor {alpha} is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis
Carcinogenesis, April 1, 2000; 21(4): 823 - 826.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. Desvergne and W. Wahli
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism
Endocr. Rev., October 1, 1999; 20(5): 649 - 688.
[Abstract] [Full Text]

Home page
 CarcinogenesisHome page
S. Chevalier and R.A. Roberts
G1-arrested FaO cells re-enter the cell cycle upon stimulation with the rodent non-genotoxic hepatocarcinogen nafenopin
Carcinogenesis, July 1, 1999; 20(7): 1209 - 1213.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
S Chevalier, N Macdonald, and R. Roberts
Induction of DNA replication by peroxisome proliferators is independent of both tumour necrosis factor (alpha) priming and EGF-receptor tyrosine kinase activity
J. Cell Sci., January 12, 1999; 112(24): 4785 - 4791.
[Abstract] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kersten, S. Mandard, N. S. Tan, P. Escher, D. Metzger, P. Chambon, F. J. Gonzalez, B. Desvergne, and W. Wahli
Characterization of the Fasting-induced Adipose Factor FIAF, a Novel Peroxisome Proliferator-activated Receptor Target Gene
J. Biol. Chem., September 8, 2000; 275(37): 28488 - 28493.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.